News
RetinAI & OptymEdge Collaborate to Accelerate Ophthalmic Drug Development Through AI-Powered Reading Center Solutions
This collaboration focuses on exploring the integration of RetinAI Discovery® and advanced AI capabilities with OptymEdge's Reading center to optimize clinical trial workflows and accelerate time-to-market for new therapies.
Ikerian AG (RetinAI's parent company) and OptymEdge announced a partnership to optimize clinical trial workflows through integrated AI analysis and imaging management. The companies will combine the RetinAI Discovery® platform with OptymEdge's Acuvera platform to streamline ophthalmic imaging workflows using automated biomarker detection.
RetinAI/Ikerian AG was established in 2017. OptymEdge brings 30+ years of experience and supports 2,500+ clinical sites.
“Integrating advanced analytics and AI into the foundational layer of Reading Center services is no longer just an advantage, it is a necessity for the future of clinical trials.”
“By exploring the integration of the RetinAI Discovery® platform and its AI-driven advanced analytics with our Acuvera Platform, we are creating a more agile, digital Reading Center.”
“The future of reading centers lies in intelligent, integrated platforms.”